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TO THE EDITOR
We wish to report the characteristic
differences that have been identified
between the ceramide (CER) profiles
of atopic dermatitis (AD) patients and
those of healthy individuals.
AD is characterized by impaired
stratum corneum (SC) functions, which
can be indicated by either an increase
in transepidermal water loss (TEWL) or
a decrease in water-holding function
(capacitance). On the other hand, a
close relationship between the im-
paired SC functions and CERs has been
reported (Elias, 1983; Melnik et al.,
1988; Yamamoto et al., 1991; Motta
et al., 1993, Paige et al., 1994; Di
Nardo et al., 1998; Matsumoto et al.,
1999; Macheleidt et al., 2002; Cho
et al., 2004). More recent research has
attempted—but failed—to uncover the
diagnostic potential of CER profiling
for skin pathologies, including AD
(Farwanah et al., 2005).
Human SC CERs can be divided into
11 groups according to their fatty acid
and sphingoid structures (Masukawa
et al., 2008), as shown in Figure 1a:
CER[NDS] contains non-OH fatty
acids [N] and dihydrosphingosines
[DS]; CER[NS] contains [N] and sphin-
gosines [S]; CER[NH] contains [N] and
6-hydroxy sphingosines [H]; CER[NP]
contains [N] and phytosphingosines
[P]; CER[ADS] contains a-OH fatty
acids [A] and [DS]; CER[AS] contains
[A] and [S]; CER[AH] contains [A] and
[H]; CER[AP] contains [A] and [P];
CER[EOS] contains ester-linked fatty
acids, and o-OH fatty acids [EO] and
[S]; CER[EOH] contains [EO] and [H];
and CER[EOP] contains [EO] and [P].
These classes have been further sub-
divided into species by chain length.
To date, we have identified 350 species
in human SC, using normal-phase
liquid chromatography coupled with
electrospray ionization–mass spectro-
metry (Masukawa et al., 2008, 2009;
it is worth noting that the former was
used to separate CERs into classes
based on the polarities). Using the same
procedure, we obtained an exhaustive
CER profile of the skin of AD patients
and healthy individuals to find a char-
acteristic difference between their pro-
files.
The study was conducted according
to the Declaration of Helsinki Princi-
ples. The protocol was approved by the
ethics committees of the Kao Corpora-
tion and Dokkyo Medical University.
Informed consent to participate in this
study was obtained from the patients.
Eight subjects with mild levels of AD
(four men and four women; age
range, 16–37; mean, 28) and seven
healthy individuals with no history of
skin disorder (four men and three
women; age range, 25–37; mean, 31)
were enrolled in this study. First, we
evaluated TEWL and capacitance, res-
pectively, using a Tewameter TM
210 and a Corneometer CM 825
(CourageþKhazaka Electronic GmbH,
Cologne, Germany) in the affected
and unaffected sites on the forearm
skin of AD patients and on the forearm
skin of healthy individuals. After con-
firming that TEWL and capacitance
were significantly higher and lower,
respectively, in the affected sites of the
AD patients as compared with those of
the unaffected sites of the AD patients
and healthy individuals (Figure 1b and
c), we sampled SC specimens from
these skin sites by performing tape
stripping 10 times. CERs were in turn
extracted from these specimens and
analyzed with an Agilent 1100
Series LC/MSD single-quadrupole sys-
tem equipped with an electrospray
ionization source, ChemStation soft-
ware, a 1,100-well-plate autosampler
(Agilent Technologies, Palo Alto, CA),
and an Inertsil SIL 100A-3, 1.5mm
i.d. 150mm column (GL Science,
Tokyo, Japan). These procedures are
detailed in our previous reports
(Masukawa et al., 2008, 2009).
The levels of total CER as well as
those of CER[NH], CER[NP], CER[EOS],
CER[EOH], and CER[EOP] classes were
found to be significantly lower in the
affected sites of AD patients as com-
pared with the normal skin sites of
healthy individuals (Figure 1d and e).
These findings are consistent with
previous findings (Imokawa et al.,
1991; Yamamoto et al., 1991; Di Nardo
et al., 1998; Bleck et al., 1999; Mache-
leidt et al., 2002). In addition, this study
revealed that the expression levels of
CER[AS] were significantly higher in the
affected sites of AD patients as com-
pared with the normal sites of healthy
individuals.
Abbreviations: AD, atopic dermatitis; CER, ceramide; SC, stratum corneum; TEWL, transepidermal water
loss
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A significant difference was further
detected by dividing each class into
species. As a result, we found in
AD patients that the larger species
(450 total carbons) of the CER[NS],
CER[NDS], CER[NH], CER[AS], and
CER[AH] tended to be expressed at
lower levels, whereas the smaller
species (o40 total carbons) of the
CER[NS], CER[NDS], and CER[AS]
tended to be expressed at higher levels
than the equivalent levels in healthy
individuals. A typical example of this
tendency is CER[NS] (illustrated in
Figure 1f), in which the smaller species
(o40 total carbons) were expressed at
significantly higher levels and the larger
species (450 total carbons) were
expressed at significantly lower levels
in the affected sites of AD patients as
compared with those of healthy indivi-
duals.
In addition, we detected a parameter
that reflects the SC barrier impairments
in the CER profile. A correlation with
the values of SC barrier functions was
detected in the expression level of CER
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Figure 1. Stratum Corneum (SC) functions and ceramide profiles in AD patients and healthy subjects. (a) Structure and nomenclature of ceramides
from the human SC. The mean values of (b) transepidermal water loss (TEWL), (c) capacitance, and the mean levels of (d) total ceramides, of (e) each
ceramide class, and of (f) each species in CER[NS] in the affected and unaffected sites of AD patients (n¼8) and in the normal skin sites of healthy
individuals (n¼ 7) are indicated by black, gray, and white bars, respectively. The uppercase letters (A, B) denote significant difference by Bonferroni’s
post hoc multiple comparison test (Po0.05 and Po0.01, respectively).
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(total, class) and also in the average
number of carbon atoms in each CER
class. Table 1a and b summarizes the
correlation coefficients and their
significance. Previously, a significant
negative correlation with TEWL value
was found in both the content ratio and
the quantity of CER[NP], and a signifi-
cant positive correlation was found in
the content ratio of CER[AH] (Di Nardo
et al., 1998). In our study, a significant
correlation with TEWL value was
observed but was not limited to the
two classes. A strong correlation with
the impaired SC barrier functions was
found in the expression level of
C34-CER[NS] as well as in the average
number of carbon atoms of CER[EOP],
whereas a strong correlation with the
improved SC barrier functions was
found in the expression levels of
CER[NDS], CER[NH], CER[AH], CER
[AP], CER[EOS], CER[EOH], and CER
[EOP] and in the average number of
carbon atoms of CER[NDS], CER[NS],
CER[NH], CER[AS], and CER[AH].
Taken together, our findings suggest
that the CER profile is a candidate
marker for the diagnosis and prognosis
of AD.
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TO THE EDITOR
Malignant melanoma is one of the least
chemosensitive human cancers. The
cause of drug resistance in melanoma
remains poorly understood. So far, no
cytotoxic regimen has revealed superio-
rity compared to dacarbazine mono-
therapy (Eggermont and Kirkwood, 2004).
Although mutations inactivating the
TP53 gene (encoding the p53 protein)
are rare events in melanoma (Hartmann
et al., 1996), p53 may be inactivated
through other mechanisms. The murine
double-minute oncogene (MDM2) binds
to and ubiquitinates p53 (Piette et al.,
1997), and MDM2 amplification has
been found responsible for p53 inactiva-
tion in some malignancies (Momand
et al., 1998). Recently, an MDM2
promoter polymorphism (SNP309T4G)
increasing MDM2 expression through
enhanced binding of the Sp1 transcrip-
tional activator was shown to enhance
carcinogenesis (Bond et al., 2004).
p14ARF activates p53 by inhibiting
MDM2 binding (Figure 1a); thus, loss of
p14ARF may reduce p53 function
(Efeyan and Serrano, 2007). Although
p14ARF in general is activated in
response to oncogenic stimulation, there
is evidence that p14ARF may also be
involved in response to genotoxic stress
(Christophorou et al., 2006). p14ARF is
encoded by ‘‘the alternative reading
frame’’ of the CDKN2A gene. Although
most CDKN2A mutations identified in
melanoma affect the p16INK4a tran-
script only (Grafstrom et al., 2005;
Knappskog et al., 2006; Goldstein
et al., 2007), mutations affecting the 50
half of exon 2 may affect both transcripts.
Here, we analyzed pretreatment
tumor biopsies from 85 patients
receiving dacarbazine for advanced
malignant melanoma (Busch et al.,
unpublished data) for potential distur-
bances in p53, MDM2, p14ARF, or
p16INK4a. Pretreatment biopsies from
all patients were snap frozen in liquid
nitrogen. Each patient provided written
informed consent, and the study
protocol was approved by the regional
ethical committee. The study was
conducted according to the Declaration
of Helsinki Principles. Of the 85 pati-
ents, 75 were evaluable for clinical
response according to the UICC-criteria
(Busch et al., unpublished data). RNA
was extracted with TRIzol (Invitrogen,
Carlsbad, CA), and cDNA was synthe-
sized with reverse transcriptase (Roche
Diagnostics, Basel, Switzerland). The
tumors were screened for TP53 and
CDKN2a mutations andMDM2 promo-
ter status by PCR amplification and
subsequent sequencing. In addition,
intragenetic deletions or amplifications
in CDKN2A or MDM2 were screened
for using MLPA (MRC Holland,
Amsterdam, the Netherlands; Schouten
et al., 2002). mRNA expression
analysis of p16INK4a and BMI-1 was
performed in a duplex qRT-PCR system
(LightCycler 480; Roche Diagnostics)
using TaqMan probes and b-2-micro-
globulin as an internal reference.
Dilutions of PCR products of these
genes were included in each run to
make a standard curve for calculation
of relative concentrations.
We considered the ‘‘p53 pathway’’
to be disturbed in tumors harboring
one of the following events: TP53 or
p14ARF mutations causing amino-acid
changes, biallelic p14ARF deletions,
MDM2 amplification, and/or homozyg-
osity for the SNP309G haplotype.
To evaluate the impact of p16INK4a
expression levels, we compared tumors
expressing p16INK4a above or below
median of the analyzed samples.
Potential correlations between
molecular parameters and clinical
outcome were tested using the Fisher’s
exact test comparing objective respon-
ders (complete response or partial
response) to nonresponders (progressive
disease or stable disease) or stable
disease þ complete response/partial
response versus progressive disease.
Univariate analyses were performed
analyzing different factors impact on
time to progression and overall survival
(OS) using log-rank test. Variables
with P-value o0.10 were entered into
Abbreviations: BMI-1, polycomb ring finger oncogene; MDM2, mouse double-minute homolog;
OS, overall survival
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